Patients suffering ED happy with Vardenafil drugs

BOSTON - The Journal of Sexual Medicine has published the findings of the head to head trial of PDE5 inhibitors, for treatment in patients with erectile dysfunction (ED). The study was an effort in drawing a methodical comparison of vardenafil and sildenafil treatment in men with ED and diabetes, hypertension, and/or hyperlipidemia. The results showed that vardenafil was more efficient and patients showed preference for the use of this drug.

A total of 1,057 men participated in the study, which involved treatment using each drug for four weeks, with a one-week washout period in between. Patients were asked: 'Overall, which medication do you prefer?' along with 11 other preference questions relating to their ED treatment. Additional efficacy assessments using established scales were also used in analysis.

Data showed that 38.9% preferred vardenafil compared to 34.5% sildenafil (26.6% had no preference). Vardenafil was significantly superior to sildenafil in terms of erectile function, intercourse satisfaction and overall satisfaction. There were also a significant higher percentage of positive responses for vardenafil with regards to erection hardness for penetration, maintenance of erection, maintenance until completion, and erection confidence.

'This study represents an important step forward in our understanding of the clinical differences between PDE5 inhibitors, confirming the efficacy of vardenafil for men with erectile dysfunction,' explains Irwin Goldstein, study co-author and Editor-in-Chief of The Journal of Sexual Medicine.

There are currently three PDE5 inhibitors available to treat ED: sildenafil, tadalafil and vardenafil, all of which have previously demonstrated efficacy and tolerability in a range of patient populations, according to researchers.

Data from head-to-head clinical trials, like this one, are scarce. However, results from studies such as this should help clinicians to differentiate among sildenafil, vardenafil, and tadalafil and to select the most appropriate for individual patients.

Source-Eurekalert
SAV